Literature DB >> 30221154

Cohort contributions to trends in the incidence and mortality of intrahepatic cholangiocarcinoma.

Eliza W Beal1, Dmitry Tumin2, Dimitrios Moris1, Xu-Feng Zhang1,3, Jeffery Chakedis1, Mary Dilhoff1, Carl M Schmidt1, Timothy M Pawlik1.   

Abstract

BACKGROUND: The incidence and mortality of intrahepatic cholangiocarcinoma (ICC) are increasing worldwide. We used age-period-cohort (APC) modeling to evaluate the contribution of cohort effects to trends in ICC incidence and mortality in the US.
METHODS: Incidence data were acquired from the Surveillance, Epidemiology and End-Results (SEER) program. Mortality data were obtained from the Centers for Disease Control and Prevention WONDER Database. APC models using restricted cubic splines were fitted to estimate change in incidence and mortality risk over age, and modification of incidence and mortality risks according to birth cohort and period of diagnosis or death. Likelihood ratio tests were used to summarize improvement in model fit with APC modeling.
RESULTS: There were 4,053 cases of ICC at SEER registry sites between 1973-2012. ICC incidence increased with older age and across all birth cohorts examined. Inclusion of cohort effects tended to improve model fit relative to an age-period model (likelihood ratio test P=0.082). The national crude ICC-related mortality rate increased from 2.9 to 5.0 per 100,000 among males and 2.7 to 4.6 per 100,000 among females. Among males, ICC mortality risk varied across birth cohorts, and inclusion of cohort effects in a model predicting ICC mortality risk improved model fit (likelihood ratio test P=0.001), but cohort effects did not alter model fit among females (P=0.223).
CONCLUSIONS: ICC incidence and mortality have increased over time in the United States. Birth cohort effects influenced increased ICC incidence and ICC mortality among males, but were not evident in the trend of ICC mortality among females.

Entities:  

Keywords:  Intrahepatic cholangiocarcinoma (ICC); age-period-cohort model (APC model); cohort effect; incidence; mortality

Year:  2018        PMID: 30221154      PMCID: PMC6131266          DOI: 10.21037/hbsn.2018.03.16

Source DB:  PubMed          Journal:  Hepatobiliary Surg Nutr        ISSN: 2304-3881            Impact factor:   7.293


  25 in total

1.  Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States.

Authors:  T Patel
Journal:  Hepatology       Date:  2001-06       Impact factor: 17.425

2.  Age-period-cohort models for the Lexis diagram.

Authors:  B Carstensen
Journal:  Stat Med       Date:  2007-07-10       Impact factor: 2.373

3.  Intrahepatic cholangiocarcinoma: expert consensus statement.

Authors:  Sharon M Weber; Dario Ribero; Eileen M O'Reilly; Norihiro Kokudo; Masaru Miyazaki; Timothy M Pawlik
Journal:  HPB (Oxford)       Date:  2015-08       Impact factor: 3.647

4.  Intrahepatic cholangiocarcinoma.

Authors:  Kimberly M Brown; Abhishek D Parmar; David A Geller
Journal:  Surg Oncol Clin N Am       Date:  2014-04       Impact factor: 3.495

5.  Prevalence of nonalcoholic steatohepatitis among patients with resectable intrahepatic cholangiocarcinoma.

Authors:  Srinevas K Reddy; Omar Hyder; J Wallis Marsh; Georgios C Sotiropoulos; Andreas Paul; Sorin Alexandrescu; Hugo Marques; Carlo Pulitano; Eduardo Barroso; Luca Aldrighetti; David A Geller; Christine Sempoux; Vlad Herlea; Irinel Popescu; Robert Anders; Laura Rubbia-Brandt; Jean-Francois Gigot; Giles Mentha; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2013-01-25       Impact factor: 3.452

6.  Defining the possible therapeutic benefit of lymphadenectomy among patients undergoing hepatic resection for intrahepatic cholangiocarcinoma.

Authors:  Alessandro Vitale; Mohamed Moustafa; Gaya Spolverato; Faiz Gani; Umberto Cillo; Timothy M Pawlik
Journal:  J Surg Oncol       Date:  2016-03-03       Impact factor: 3.454

7.  Rising trends in cholangiocarcinoma: is the ICD classification system misleading us?

Authors:  Shahid A Khan; Shireen Emadossadaty; Nimzing G Ladep; Howard C Thomas; Paul Elliott; Simon D Taylor-Robinson; Mireille B Toledano
Journal:  J Hepatol       Date:  2011-12-13       Impact factor: 25.083

8.  Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study.

Authors:  Christina Fitzmaurice; Christine Allen; Ryan M Barber; Lars Barregard; Zulfiqar A Bhutta; Hermann Brenner; Daniel J Dicker; Odgerel Chimed-Orchir; Rakhi Dandona; Lalit Dandona; Tom Fleming; Mohammad H Forouzanfar; Jamie Hancock; Roderick J Hay; Rachel Hunter-Merrill; Chantal Huynh; H Dean Hosgood; Catherine O Johnson; Jost B Jonas; Jagdish Khubchandani; G Anil Kumar; Michael Kutz; Qing Lan; Heidi J Larson; Xiaofeng Liang; Stephen S Lim; Alan D Lopez; Michael F MacIntyre; Laurie Marczak; Neal Marquez; Ali H Mokdad; Christine Pinho; Farshad Pourmalek; Joshua A Salomon; Juan Ramon Sanabria; Logan Sandar; Benn Sartorius; Stephen M Schwartz; Katya A Shackelford; Kenji Shibuya; Jeff Stanaway; Caitlyn Steiner; Jiandong Sun; Ken Takahashi; Stein Emil Vollset; Theo Vos; Joseph A Wagner; Haidong Wang; Ronny Westerman; Hajo Zeeb; Leo Zoeckler; Foad Abd-Allah; Muktar Beshir Ahmed; Samer Alabed; Noore K Alam; Saleh Fahed Aldhahri; Girma Alem; Mulubirhan Assefa Alemayohu; Raghib Ali; Rajaa Al-Raddadi; Azmeraw Amare; Yaw Amoako; Al Artaman; Hamid Asayesh; Niguse Atnafu; Ashish Awasthi; Huda Ba Saleem; Aleksandra Barac; Neeraj Bedi; Isabela Bensenor; Adugnaw Berhane; Eduardo Bernabé; Balem Betsu; Agnes Binagwaho; Dube Boneya; Ismael Campos-Nonato; Carlos Castañeda-Orjuela; Ferrán Catalá-López; Peggy Chiang; Chioma Chibueze; Abdulaal Chitheer; Jee-Young Choi; Benjamin Cowie; Solomon Damtew; José das Neves; Suhojit Dey; Samath Dharmaratne; Preet Dhillon; Eric Ding; Tim Driscoll; Donatus Ekwueme; Aman Yesuf Endries; Maryam Farvid; Farshad Farzadfar; Joao Fernandes; Florian Fischer; Tsegaye Tewelde G/Hiwot; Alemseged Gebru; Sameer Gopalani; Alemayehu Hailu; Masako Horino; Nobuyuki Horita; Abdullatif Husseini; Inge Huybrechts; Manami Inoue; Farhad Islami; Mihajlo Jakovljevic; Spencer James; Mehdi Javanbakht; Sun Ha Jee; Amir Kasaeian; Muktar Sano Kedir; Yousef S Khader; Young-Ho Khang; Daniel Kim; James Leigh; Shai Linn; Raimundas Lunevicius; Hassan Magdy Abd El Razek; Reza Malekzadeh; Deborah Carvalho Malta; Wagner Marcenes; Desalegn Markos; Yohannes A Melaku; Kidanu G Meles; Walter Mendoza; Desalegn Tadese Mengiste; Tuomo J Meretoja; Ted R Miller; Karzan Abdulmuhsin Mohammad; Alireza Mohammadi; Shafiu Mohammed; Maziar Moradi-Lakeh; Gabriele Nagel; Devina Nand; Quyen Le Nguyen; Sandra Nolte; Felix A Ogbo; Kelechi E Oladimeji; Eyal Oren; Mahesh Pa; Eun-Kee Park; David M Pereira; Dietrich Plass; Mostafa Qorbani; Amir Radfar; Anwar Rafay; Mahfuzar Rahman; Saleem M Rana; Kjetil Søreide; Maheswar Satpathy; Monika Sawhney; Sadaf G Sepanlou; Masood Ali Shaikh; Jun She; Ivy Shiue; Hirbo Roba Shore; Mark G Shrime; Samuel So; Samir Soneji; Vasiliki Stathopoulou; Konstantinos Stroumpoulis; Muawiyyah Babale Sufiyan; Bryan L Sykes; Rafael Tabarés-Seisdedos; Fentaw Tadese; Bemnet Amare Tedla; Gizachew Assefa Tessema; J S Thakur; Bach Xuan Tran; Kingsley Nnanna Ukwaja; Benjamin S Chudi Uzochukwu; Vasiliy Victorovich Vlassov; Elisabete Weiderpass; Mamo Wubshet Terefe; Henock Gebremedhin Yebyo; Hassen Hamid Yimam; Naohiro Yonemoto; Mustafa Z Younis; Chuanhua Yu; Zoubida Zaidi; Maysaa El Sayed Zaki; Zerihun Menlkalew Zenebe; Christopher J L Murray; Mohsen Naghavi
Journal:  JAMA Oncol       Date:  2017-04-01       Impact factor: 31.777

9.  Forty-Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise.

Authors:  Supriya K Saha; Andrew X Zhu; Charles S Fuchs; Gabriel A Brooks
Journal:  Oncologist       Date:  2016-03-21

10.  Healthcare utilization and costs associated with cholangiocarcinoma.

Authors:  Vaibhav Wadhwa; Yash Jobanputra; Prashanthi N Thota; K V Narayanan Menon; Mansour A Parsi; Madhusudhan R Sanaka
Journal:  Gastroenterol Rep (Oxf)       Date:  2016-08-10
View more
  12 in total

1.  Trends in the Incidence, Treatment and Outcomes of Patients with Intrahepatic Cholangiocarcinoma in the USA: Facility Type is Associated with Margin Status, Use of Lymphadenectomy and Overall Survival.

Authors:  Lu Wu; Diamantis I Tsilimigras; Anghela Z Paredes; Rittal Mehta; J Madison Hyer; Katiuscha Merath; Kota Sahara; Fabio Bagante; Eliza W Beal; Feng Shen; Timothy M Pawlik
Journal:  World J Surg       Date:  2019-07       Impact factor: 3.352

2.  Increasing mortality of intrahepatic cholangiocarcinoma in the US: are gender-specific risk factors important?

Authors:  Samuel O Antwi; Tushar Patel
Journal:  Hepatobiliary Surg Nutr       Date:  2019-12       Impact factor: 7.293

Review 3.  Intrahepatic cholangiocarcinoma: Morpho-molecular pathology, tumor reactive microenvironment, and malignant progression.

Authors:  Alphonse E Sirica; Mario Strazzabosco; Massimiliano Cadamuro
Journal:  Adv Cancer Res       Date:  2020-12-09       Impact factor: 6.242

4.  MicroRNA‑137 suppresses the proliferation, migration and invasion of cholangiocarcinoma cells by targeting WNT2B.

Authors:  Tengxiang Chen; Shan Lei; Zhirui Zeng; Shutao Pan; Jinjuan Zhang; Yan Xue; Yuanmei Sun; Jinzhi Lan; Su Xu; Dahua Mao; Bing Guo
Journal:  Int J Mol Med       Date:  2020-01-23       Impact factor: 4.101

5.  The diagnostic and prognostic value of UBE2T in intrahepatic cholangiocarcinoma.

Authors:  Hua Yu; Han Wang; Wei Dong; Zhen-Ying Cao; Rong Li; Chao Yang; Wen-Ming Cong; Hui Dong; Guang-Zhi Jin
Journal:  PeerJ       Date:  2020-01-27       Impact factor: 2.984

6.  MRPL27 contributes to unfavorable overall survival and disease-free survival from cholangiocarcinoma patients.

Authors:  Liping Zhuang; Zhiqiang Meng; Zongguo Yang
Journal:  Int J Med Sci       Date:  2021-01-01       Impact factor: 3.738

Review 7.  Challenges and Opportunities for Treating Intrahepatic Cholangiocarcinoma.

Authors:  Nikolaos Serifis; Diamantis I Tsilimigras; Daniel J Cloonan; Timothy M Pawlik
Journal:  Hepat Med       Date:  2021-11-02

8.  A simple scoring system to estimate perioperative mortality following liver resection for primary liver malignancy-the Hepatectomy Risk Score (HeRS).

Authors:  Dimitrios Moris; Brian I Shaw; Cecilia Ong; Ashton Connor; Mariya L Samoylova; Samuel J Kesseli; Nader Abraham; Jared Gloria; Robin Schmitz; Zachary W Fitch; Bryan M Clary; Andrew S Barbas
Journal:  Hepatobiliary Surg Nutr       Date:  2021-06       Impact factor: 7.293

9.  Resection of intrahepatic cholangiocarcinoma in elderly patients - is it reasonable?

Authors:  Fabian Bartsch; Janine Baumgart; Verena Tripke; Maria Hoppe-Lotichius; Stefan Heinrich; Hauke Lang
Journal:  BMC Surg       Date:  2019-10-29       Impact factor: 2.102

10.  Latent Risk Intrahepatic Cholangiocarcinoma Susceptible to Adjuvant Treatment After Resection: A Clinical Deep Learning Approach.

Authors:  Seogsong Jeong; Yang Ge; Jing Chen; Qiang Gao; Guijuan Luo; Bo Zheng; Meng Sha; Feng Shen; Qingbao Cheng; Chengjun Sui; Jingfeng Liu; Hongyang Wang; Qiang Xia; Lei Chen
Journal:  Front Oncol       Date:  2020-02-19       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.